In vitro Biotransfonnation of U-89843 and Its Deuterated Analog, U-141030

Loading...
Thumbnail Image
Authors
Perdue, Aaron M.
Issue Date
1998
Type
Thesis
Language
en_US
Keywords
Research Projects
Organizational Units
Journal Issue
Alternative Title
Abstract
U-89843 is an important member of a lipid peroxidation family that are important biologically. This drug was initially pursued by Pharmacia & Upjohn, Inc. for the treatment of asthma. However, due to its observed genotoxicity, it is no longer considered a drug candidate. Therefore, U-89843 and its deuterated analog, U-141030, were studied in vitro in rat and human hepatic microsomes to determine characteristics of the biotransformation of U-89843 so the mechanistic pathway that forms its reactive intermediate can be determined. With this knowledge, it is hoped that new drug analogs of U-89843 can be developed that are not genotoxic but still prove valuable for the treatment of asthma. The measured isotope effect for the formation of U-97924 was found to be 1.25 and 1.2 at 0.27 and 0.5 µM P450, respectively. These values are indicative of a secondary isotope effect. A secondary isotope effect leads one to believe that the mechanism responsible for the formation of U-97924 from U-89843 involves electron abstraction followed by the addition of OH from water. Km and V max were determined for U-89843 and U-141030 in untreated, pooled rat microsomes (Km = 4.09 µM and Vmax = 18.18 nmol/mg/min; Km= 3.36 µM and Vmax = 17.86 nmol/mg/min, respectively) and human microsomes (Km = 21.87 µM and V max = 0.93 nmol/mg/min; Km= 8.80 µM and V max = 0.33 nmol/mg/min, respectively). The human P450 isoform responsible for the biotransformation of U-89843 was found to be CYP3A4.
Description
vii, 47 p.
Citation
Publisher
License
U.S. copyright laws protect this material. Commercial use or distribution of this material is not permitted without prior written permission of the copyright holder. All rights reserved.
Journal
Volume
Issue
PubMed ID
DOI
ISSN
EISSN